COVID-19 impact in Crohn’s disease patients submitted to autologous hematopoietic stem cell transplantation

Table 2 General Statistics of the Crohn disease patients underwent to autologous hematopoietic stem cell transplantation and coronavirus disease 2019 (50 pts. 2013-2021), n (%)/mean ± SD

		COVID-19 positive patients, 19 (38%)	COVID-19 negative patients, 31 (62%)
Sex	Female	12 (42.85)	16 (57.14)	0.4251
	Male	7 (31.81)	15 (68.18)
Age (yr)		39.11 ± 10.104	37.52 ± 8.84	0.5622
Elapsed time HSCT until evaluation (month)		46.05 ± 24.19	48.71 ± 28.12	0.7342
Elapsed time HSCT until COVID-19 +		39.47 ± 26.57
COVID-19 vaccination	Yes	9 (23.1)	30 (76.9)
	No	10 (90.90)	1 (9.1)
CD status before COVID-19	Relapsed	8 (28.57)	20 (71.42)	0.15003
	Remission	11 (50)	11 (50)
CD status after COVID-19	Relapsed	11 (35.48)	20 (64.52)	0.76613
	Remission	8 (42.10)	11 (57.89)

¹Pearson Chi-square test.

²t-test.

³Fisher's exact test.

CD: Crohn's disease; COVID-19: Coronavirus disease 2019; HSCT: Hematopoietic stem cell transplantation.